| 16.9358 -0.464 (-2.67%) | 10-16 10:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 26.22  |
1-year : | 30.29 |
| Resists | First : | 22.45 |
Second : | 25.94 |
| Pivot price | 19.57 |
|||
| Supports | First : | 16.81 |
Second : | 13.98 |
| MAs | MA(5) : | 17.66 |
MA(20) : | 20.62 |
| MA(100) : | 22.86 |
MA(250) : | 21.76  |
|
| MACD | MACD : | -2 |
Signal : | -1.7 |
| %K %D | K(14,3) : | 3.2 |
D(3) : | 3.2 |
| RSI | RSI(14): 23.2 |
|||
| 52-week | High : | 30.05 | Low : | 14.64 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IMNM ] has closed above bottom band by 10.9%. Bollinger Bands are 27.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.62 - 17.72 | 17.72 - 17.83 |
| Low: | 16.83 - 16.95 | 16.95 - 17.07 |
| Close: | 17.21 - 17.39 | 17.39 - 17.57 |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Fri, 16 Oct 2026
William Blair initiates Immunome stock coverage with outperform rating - Investing.com
Thu, 15 Oct 2026
Immunome clears FDA IND for IM-1340: what it means for Immunome stock - ad-hoc-news.de
Wed, 14 Oct 2026
Immunome, Inc. (IMNM) stock price, news, quote and history - Yahoo Finance UK
Wed, 14 Oct 2026
Immunome, Inc. (IMNM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 06 Oct 2026
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fri, 02 Oct 2026
Immunome, Inc. (IMNM) stock price, news, quote and history - Yahoo Finance Australia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 118 (M) |
| Shares Float | 109 (M) |
| Held by Insiders | 6.3 (%) |
| Held by Institutions | 102.8 (%) |
| Shares Short | 16,760 (K) |
| Shares Short P.Month | 15,630 (K) |
| EPS | -2.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.8 % |
| Return on Equity (ttm) | -64.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.75 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -209 (M) |
| Levered Free Cash Flow | -144 (M) |
| PE Ratio | -6.74 |
| PEG Ratio | 0 |
| Price to Book value | 3.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|